Towards Healthcare
Antitumor ADC Drugs Market Trends and Companies

Antitumor ADC Drugs Market Thrives with Biopharma Boost

Rising cancer incidence/unmet needs have driven the growth of the market. North America led the global market owing to a strong R&D pipeline & biopharmaceutical innovations in the region.

Content

  • Last Updated: 27 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The antitumor ADC drugs market currently is poised for massive expansion by 2034, led by evolving consumer needs and cutting-edge technologies.

North America is leading the antitumor ADC drugs market share by 55% due to the growing prevalence of the cancer, increasing research & development activities and presence of major key players.

The antitumor ADC drugs market includes 8 segments including by drug type, by payload type, by linker technology, by target antigen therapeutic area, by route of administration, by distribution channel and by region.

Some key players include Seattle Genetics, Inc. (Seagen), Roche Holding AG, ImmunoGen, Inc., Daiichi Sankyo Company, Limited, Pfizer Inc., Amgen Inc., AstraZeneca plc and AbbVie Inc.

Indian Drug Manufacturers Association (IDMA), Government of Canada, Indian Pharmaceutical Association (IPA), Food and Drug Administration, Association for Accessible Medicines, Drug Information Association
Any Questions